Dendreon Corporation 소개
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.
Source: Wikipedia
본사Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
설립2013
상태운영 중
특허특허 134건
HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH…CA2923433C · 2020
Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with…US10261091B2 · 2019
법적 정보
| 법인명 | Dendreon Corporation |
|---|---|
| LEI | 549300C0XK81HDI8KK82GLEIF에서 보기 ↗ |
| 등기 주소 | Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US |
| 상태 | 운영 중 |
출처: GLEIF · 2026년 10월 16일 업데이트
연락처 및 링크
위치
Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
귀하의 회사인가요?
이 페이지를 무료로 신청하여 로고, 제품, 사진, 채용 공고를 추가하고 리뷰에 답변하세요.
이 페이지 신청